Loading...
XTAENVLG
Market cap250mUSD
Dec 24, Last price  
178.80ILS
1D
-0.72%
1Q
20.97%
IPO
6.87%
Name

Novolog Pharm Up 1966 Ltd

Chart & Performance

D1W1MN
XTAE:NVLG chart
P/E
—
P/S
55.57
EPS
—
Div Yield, %
0.02%
Shrs. gr., 5y
7.86%
Rev. gr., 5y
12.52%
Revenues
1.64b
+8.99%
542,786,000629,007,000683,303,000739,219,000839,837,000911,239,0001,004,138,0001,133,643,0001,255,248,0001,507,949,0001,643,489,000
Net income
-42m
L
14,788,00023,539,00025,257,00029,121,00022,492,00021,861,00010,137,00040,067,00042,318,00047,510,000-42,003,000
CFO
200m
+50.78%
-55,793,000160,595,000140,292,00020,283,00086,372,00023,963,000101,454,00058,485,00083,387,000132,648,000200,013,000
Dividend
Sep 03, 20242.93687 ILS/sh

Profile

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.
URL
https://www.novolog.co.il/
IPO date
Feb 28, 2017
Employees
926
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,643,489
8.99%
1,507,949
20.13%
1,255,248
10.73%
Cost of revenue
1,593,017
1,348,391
1,118,664
Unusual Expense (Income)
NOPBT
50,472
159,558
136,584
NOPBT Margin
3.07%
10.58%
10.88%
Operating Taxes
10,474
17,128
15,305
Tax Rate
20.75%
10.73%
11.21%
NOPAT
39,998
142,430
121,279
Net income
(42,003)
-188.41%
47,510
12.27%
42,318
5.62%
Dividends
(16,900)
(31,900)
(32,000)
Dividend yield
2.33%
2.23%
2.09%
Proceeds from repurchase of equity
119,830
BB yield
-7.84%
Debt
Debt current
27,517
23,210
20,529
Long-term debt
401,859
400,220
311,791
Deferred revenue
Other long-term liabilities
19,979
9,016
5,172
Net debt
180,240
208,317
70,216
Cash flow
Cash from operating activities
200,013
132,648
83,387
CAPEX
(70,955)
(69,490)
(30,637)
Cash from investing activities
(72,603)
(124,948)
(69,070)
Cash from financing activities
(67,712)
(72,959)
47,487
FCF
55,073
75,039
78,377
Balance
Cash
232,939
172,806
238,709
Long term investments
16,197
42,307
23,395
Excess cash
166,962
139,716
199,342
Stockholders' equity
51,053
120,782
90,506
Invested Capital
580,228
556,538
507,117
ROIC
7.04%
26.78%
27.54%
ROCE
8.00%
22.96%
22.20%
EV
Common stock shares outstanding
510,922
515,793
515,076
Price
1.42
-48.70%
2.77
-6.70%
2.97
-3.29%
Market cap
726,020
-49.18%
1,428,747
-6.57%
1,529,261
5.49%
EV
931,301
1,663,116
1,605,338
EBITDA
166,013
212,412
182,272
EV/EBITDA
5.61
7.83
8.81
Interest
12,868
12,537
8,468
Interest/NOPBT
25.50%
7.86%
6.20%